Laboratoire d'Oncologie Moléculaire, UMR891 Inserm, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille, Marseille, France.
BMC Cancer. 2010 Aug 2;10:401. doi: 10.1186/1471-2407-10-401.
Gene mutation is an important mechanism of myeloid leukemogenesis. However, the number and combination of gene mutated in myeloid malignancies is still a matter of investigation.
We searched for mutations in the ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in 65 myelodysplastic syndromes (MDSs) and 64 acute myeloid leukemias (AMLs) without balanced translocation or complex karyotype.
Mutations in ASXL1 and CBL were frequent in refractory anemia with excess of blasts. Mutations in TET2 occurred with similar frequency in MDSs and AMLs and associated equally with either ASXL1 or NPM1 mutations. Mutations of RUNX1 were mutually exclusive with TET2 and combined with ASXL1 but not with NPM1. Mutations in FLT3 (mutation and internal tandem duplication), IDH1, IDH2, NPM1 and WT1 occurred primarily in AMLs.
Only 14% MDSs but half AMLs had at least two mutations in the genes studied. Based on the observed combinations and exclusions we classified the 12 genes into four classes and propose a highly speculative model that at least a mutation in one of each class is necessary for developing AML with simple or normal karyotype.
基因突变是髓系白血病发生的重要机制。然而,髓系恶性肿瘤中突变基因的数量和组合仍在研究之中。
我们在 65 例骨髓增生异常综合征(MDS)和 64 例非平衡易位或复杂核型的急性髓系白血病(AML)中搜索 ASXL1、CBL、FLT3、IDH1、IDH2、JAK2、KRAS、NPM1、NRAS、RUNX1、TET2 和 WT1 基因的突变。
ASXL1 和 CBL 突变在伴原始细胞增多的难治性贫血中频繁发生。TET2 突变在 MDS 和 AML 中发生频率相似,与 ASXL1 或 NPM1 突变的发生率相等。RUNX1 突变与 TET2 相互排斥,与 ASXL1 结合,但与 NPM1 不结合。FLT3(突变和内部串联重复)、IDH1、IDH2、NPM1 和 WT1 突变主要发生在 AML 中。
只有 14%的 MDS 但有一半的 AML 至少有 2 个研究基因的突变。基于观察到的组合和排斥,我们将这 12 个基因分为四类,并提出了一个极富推测性的模型,即至少有一个类别的突变是发生具有简单或正常核型的 AML 的必要条件。